Bone Biologics Corporation (BBLG)
After hours:
| Previous close | 0.7628 |
| Open | 0.7510 |
| Bid | 0.6700 x 800 |
| Ask | 0.7300 x 2900 |
| Day's range | 0.7301 - 0.7826 |
| 52-week range | 0.5740 - 37.1700 |
| Volume | |
| Avg. volume | 336,916 |
| Market cap | 2.35M |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.4400 |
| Earnings date | 06 Nov 2023 - 11 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
- Business Wire
Bone Biologics Prices $5.0 Million Underwritten Public Offering
BURLINGTON, Mass., June 15, 2023--Bone Biologics Corporation (NASDAQ: BBLG) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock. Bone Biologics is selling 2,538,071 shares of its common stock in the offering. The shares of common stock are being sold at a price to the public of $1.97 per share, for aggregate gross proceeds of approximately $5.0 million, before deducting
- Business Wire
Bone Biologics Effects 1-for-30 Reverse Stock Split
BURLINGTON, Mass., June 06, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on June 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted basis with the open of the market on June 7, 2023. Bone Biologics’ common stock and warrants will continue to trade on Nasdaq under the symbols "BBLG" and "BBLGW", respectively
- Business Wire
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
BURLINGTON, Mass., April 11, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.
